Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 405

1.

Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study.

Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, Gori M, Coppini A, Moghetti P.

Metabolism. 2003 Jul;52(7):862-7.

PMID:
12870162
2.
3.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
4.

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P.

Diabetes Obes Metab. 2006 Mar;8(2):156-63.

PMID:
16448519
7.

Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.

González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, Wacher-Rodarte N, Martínez-Abundis E, Aguilar-Salinas C, Islas-Andrade S, Arechavaleta-Granell R, González-Canudas J, Rodríguez-Morán M, Zavala-Suárez E, Ramos-Zavala MG, Metha R, Revilla-Monsalve C, Beltrán-Jaramillo TJ.

J Diabetes Complications. 2009 Nov-Dec;23(6):376-9. doi: 10.1016/j.jdiacomp.2008.09.002.

PMID:
18849173
9.
10.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
12.
13.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
15.
16.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
17.

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A.

Diabetes Care. 1994 Oct;17(10):1100-9.

PMID:
7821128
19.

Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.

Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C.

J Assoc Physicians India. 2003 Nov;51:1061-4.

PMID:
15260389
20.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.

PMID:
15899724
Items per page

Supplemental Content

Support Center